Fabio Tinè

Summary

Country: Italy

Publications

  1. ncbi request reprint A decade of trials of interferon-alpha for chronic hepatitis C. A meta-regression analysis
    Fabio Tinè
    Divisione di Medicina Interna e Gastroenterologia, Ospedale V Cervello, Palermo, Italy
    Contemp Clin Trials 26:179-210. 2005
  2. doi request reprint Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease
    F Tine
    Divisione di Gastroenterologia, Azienda Ospedaliera V Cervello, Palermo, Italy
    Aliment Pharmacol Ther 27:1210-23. 2008
  3. doi request reprint An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C
    Fabio Tinè
    Unità operativa di Gastroenterologia e Medicina, Ospedali Riuniti Villa Sofia e Cervello, Palermo, Italy
    Pharmacoepidemiol Drug Saf 19:1113-23. 2010

Detail Information

Publications3

  1. ncbi request reprint A decade of trials of interferon-alpha for chronic hepatitis C. A meta-regression analysis
    Fabio Tinè
    Divisione di Medicina Interna e Gastroenterologia, Ospedale V Cervello, Palermo, Italy
    Contemp Clin Trials 26:179-210. 2005
    ....
  2. doi request reprint Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease
    F Tine
    Divisione di Gastroenterologia, Azienda Ospedaliera V Cervello, Palermo, Italy
    Aliment Pharmacol Ther 27:1210-23. 2008
    ..Remission and response are the main outcomes to evaluate the efficacy of new treatments for Crohn's disease (CD)...
  3. doi request reprint An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C
    Fabio Tinè
    Unità operativa di Gastroenterologia e Medicina, Ospedali Riuniti Villa Sofia e Cervello, Palermo, Italy
    Pharmacoepidemiol Drug Saf 19:1113-23. 2010
    ..Treatment of patients with chronic hepatitis C with alpha-interferon and ribavirin usually produces adverse events within the first 3 months. We aimed to assess safety and predictors of discontinuation or dose modification of these drugs...